MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company’s Phase 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback